Cytek Biosciences has recurring revenue growth, improving margins, and ample cash that should continue compounding shareholder value over time. See why CTKB is a Buy.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global ...

ACS--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer ...

An update from bioAffinity Technologies, Inc. ( ($BIAF) ) is now available. On December 3, 2025, bioAffinity Technologies announced that it will ...

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations; Safety continues to b ...

Earlier this month, Cytek Biosciences reported third quarter results, posting revenue of US$52.29 million and a net loss of US$5.48 million, as well as reaffirming its full-year 2025 revenue guidance.

Single-cell sequencing provides unprecedented detail into cell-to-cell variability, uncovering key biological mechanisms in ...

The work grew out of decades of prostate cancer research by Michael Shen, PhD, co-leader of the Tumor Biology and ...

Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious ...

This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...